Zydus Cadila gets tentative FDA OK for lenalidomide  

Zydus Cadila has received tentative approval from the Food and Drug Administration to market lenalidomide capsules in dosage strengths of 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg.

The medication is used for the treatment of various types of cancers.

Lenalidomide works by slowing or stopping the growth of cancer cells, and also is used to treat anemia in patients with certain blood/bone marrow disorders, the company said.

The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.